Clinical Trial

A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Emerge
Protocol Amendment History 3 changes
notable Trial sites reduced: 25 -> 22 locations 2026-07-31
notable Primary completion moved earlier: 2026-11 -> 2026-05-20 2026-06-23
minor Completion moved earlier: 2027-05 -> 2027-02 2026-06-23
Trial Details
NCT Number NCT06941844
Lead Sponsor Definium Therapeutics US, Inc.
Conditions Major Depressive Disorder
Enrollment 149 participants
Start Date 2025-04-14
Primary Completion 2026-05-20 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-10